Aramex Australia and ShipStation upgrade e-commerce shipping
The latter company, formerly ‘Fastway Couriers’, currently operates in more than 60 countries and has established a reputation as one of the world’s foremost logistics companies. Aramex has 800 independent franchises established in Australia alone.
Meanwhile, ShipStation, an enterprise based in Austin, Texas, prides itself on spearheading web-based software for e-merchants to more efficiently process, fulfil and ship their orders. Founded in 2011, the company was acquired in 2014 by Stamps.com but continues to produce bold, authentic and empowering solutions.
Making e-commerce exceptional
One result of COVID-19 pandemic has been a (largely necessary) spike in online shopping as opposed to brick and mortar stores. Adobe cited a 4.1% increase in total, with grocery shopping exploding by 110% whilst electronics grew by an impressive 58%.
Potentially accelerating an already pre-existing trend as consumers move away from physical stores, ShipStation’s pledge to take online marketplace logistics to the next level couldn’t have come at a better time:
"Now more than ever, e-commerce retailers need delivery partners they can trust to deliver an exceptional last-mile delivery experience," said Krish Iyer, Head of Industry Relations and Strategic Partnerships at ShipStation.
An operational bonus for its partnership with Aramex Australia is its access to convenient parcel collection points at doorstops, as well as its Parcel Connect Service which enables packages to be collected from a range of tertiary locations, such as shops and petrol stations.
"Aramex offers the fast, affordable and predictable service that brands deserve. We're proud to add them to our network of trusted partners," added Iyer.
Laying the foundations for a better service
The excitement for the collaboration is clearly mutual, as Peter Lipinski, CEO of Aramex Australia, explains:
"At Aramex Australia, we know that convenience is king. We have laid strong foundations and have been investing in resources to ensure we deliver the best and most efficient solutions for our customers.
“Accessing the Aramex network unlocks some exciting opportunities for e-commerce retailers including international shipping to over 220 countries across the globe.
With coverage of roughly 90% of Australia’s population, access to Aramex’s network will be a substantial boost to ShipStation’s rate of growth in the APAC region. With more than 300 global partnerships now in place, the company’s mission to augment e-commerce logistics is well underway.
Seo JungJin: Who is EY’s World Entrepreneur of 2021?
Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.
Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.
JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.
Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.
Why was JungJin crowned King Entrepreneur?
A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.
The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.
According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.
Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.
“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”
How did JungJin get there?
JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.
Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.
And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.
With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.
“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”